% | $
Quotes you view appear here for quick access.

Synta Pharmaceuticals Corp. Message Board

frankyassissi 144 posts  |  Last Activity: 2 hours 9 minutes ago Member since: Dec 4, 2009
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • frankyassissi by frankyassissi Oct 31, 2015 12:40 PM Flag

    There seems to be some confusion or misinformation here. Look at the last presentation. "Plan to release data during American Society of Hematology Conference (ASH) in December."

    They have taken their time and fulfilled their timelines to date.

    What will the data look like? That's the only question outstanding. The fact is that pre-clnical results and phase 1/2 are as strong as they get. Safety is is good. Reduction of tumors pre-clinical has been proven. A diagnostic has been purchased for millions.

    Abstracts to be released Nov 5.

    Accumulation is as obvious as it gets. We're a buck below the GS/JPM buy-in. Milano in at 3.99. Bakers in at 3.99. FMR in, as well as numerous other institutions.

    Read the scientific data and follow the money.

    There is not much to gain shorting a $3 stock with this strength of science, management, and backers.On the contrary, it's an enormous risk. Name a company that has FMR, Bakers, GS, JPM, Blackstone, etc., that failed miserably. The people with the open-label info know what the results are, and they want every last retail share before results.

    Simply put, do your DD and trust it. When in doubt, get out. But don't be fooled because the catalysts are lined up for years to come, starting in about 5 days.

  • frankyassissi by frankyassissi Nov 20, 2015 11:32 AM Flag

    Lay your money down either way. Historic company data Dec 5. Milano probably took the job because he thought it'd be bad data. BB probably PRE-PAID warrants at 3.99 because they think the data will be bad. GS probably supported the company with millions at 3.75, because they think the data will be bad, and we all know GS likes to wait 5 years on their returns. JPM, same. Milano walked in the door and laid down nearly a million immediately upon arrival at open-market --- because he saw the OPEN-LABEL data, and knows it's bad. Milano opened DLBCL Phase 2, targeting the same gene as WM because the data will be bad. They have a room full of rheumatology heads of prestigious institutions because this is gong nowhere fast.

  • frankyassissi by frankyassissi Nov 9, 2015 2:19 PM Flag

    That's a surprise in the wings, guaranteed. Devastating disease, like DMD and Dermatomyositis. This is company on a focused mission. 3.50? No way GS buys 3.75 for a small bio unless they've had a thorough sit-down. At least a double BEFORE results. Afterwards, we'll see because their 8400 targets the 1 gene at this point. Why bother starting DLBCL and dermato? Confidence in the results-to-date. That's why. WM results Dec. DLBCL results April. Dermato launch today, and will be enrolled quickly. DMD, GvHD out of the blue. 2125 ---- nothing short of magnificent results.

  • Reply to

    IDRA 2.59

    by frankyassissi Aug 25, 2015 1:16 PM
    frankyassissi frankyassissi Aug 26, 2015 7:28 AM Flag

    Milano and team's well-drawn plan for execution and delivery of results and news. Following events:

    1. AACR inaugural (bi-annual international meeting) highlighting immunotherapies and the companies blazing this trail (IDRA, STML). 2 weeks out with new data on top of released data, showing 90% RR's. Big stage to present these phenomenal results.
    2. WM can come earlier than expected, anywhere from October-December). Open-label. DLBCL open-label March. Dermatomyositis open-label. All target same gene. Dermato is the biggie. They get that, they get rheumatology off-label billions. And their scientific advisory board is loaded with the best rheumatologists in the world. If WM hits, we're past 10.
    3. Dermo Ph2 this year.
    3. 3gA kickoff like the Beatles on the Abbey Road rooftop.
    4. $5bill MC in 5 years tops = ~40. Not a bad return.
    5. Goldman bought at 3.75. They don't buy #$%$. Bakers bought 3.75. FMR, JPM, Blackstone.
    6. CEO in for 800k first week hired. That speaks volumes on what he saw.

    They"re gonna unleash this monster in September, and it will be a long hard climb. Looking at these 2's is amazing. Just a month ago, people were saying no way. Here we are, and people are selling out of fear while the mammoths wipe up the blood with their greedy rags.

    Buy this. Buy STML. Buy GHDX.

  • frankyassissi by frankyassissi Nov 2, 2015 8:47 PM Flag

    From 3.35-3.83, they got em all. There's your short covering for starters, and nice price for longs to see. Keep reading, keep holding, buy anything under 3 (GL), and put your faith in your own DD. There have been quite a few subtle blocks of 50-100k shares. I'm staying with my call for 10-20 Feb-March.

  • Reply to

    Hey Franky and other longs out there

    by tradingwithyourhead Oct 9, 2015 3:55 PM
    frankyassissi frankyassissi Oct 10, 2015 6:35 PM Flag

    I think between 6 and 12 on gene targeting outcome. As I"ve said many times before, this is very binary in that they are targeting a single gene. AND, they have paid millions to single out that gene through a diagnostic. So besides WM and DLBCL, this opens the doors wide for Dermatomyositis and off-label rheumatology. The market is enormous, beyond enormous. Now, take a look at their scientific advisers and all you see are heads of rheumotology at world-renowned medical centers and schools. Throw in 3gA, 9200, and 2125, and you have something bigger than JAZZ, PCYC, etc. Just a matter of patience and due diligence.

  • frankyassissi by frankyassissi Nov 16, 2015 3:01 PM Flag

    SINGLE gene mutation. Two other trials started before data, based on same gene mutation. PHASE 2 no less. One-line bashers looking for your shares.

  • frankyassissi by frankyassissi Nov 15, 2015 4:53 PM Flag

    5's next week. WM data Dec 5. Wold not bet against an open-label phase 2 with this kind of leadership. Adding

  • Expect more of these. Divvy out small pieces of 3gA for hundreds of millions. I think GSK likes 3gA. Just like GS, BB, JPM,

  • frankyassissi by frankyassissi 2 hours 9 minutes ago Flag

    I wouldn't put this up on a new website is failure was 2 weeks away.

  • Reply to

    Long term trend change is

    by hocumsrazorissharp Sep 3, 2015 11:27 AM
    frankyassissi frankyassissi Sep 3, 2015 9:38 PM Flag

    Agree. Waited patiently for 2s again --- the 2s that no one believed would be here again just 3 weeks ago. This is where the greedy pigs take out the retail with fear, as you can clearly see with those million-dollar purchases end of day last several days. Here is what's coming, starting AACR:

    1. NEW data on 2125 kicking melanoma's #$%$ in tandem.
    2. Dermo launch Ph2
    3. 3gA targets that have been CARFULLY selected for fastest to market, unmet needs, and CLEAR, INDISPUTABLE endpoints.
    4. WM at ASH. ONE GENE. All patients have tried everything else. IDRA believes so strongly in their research that they paid out millions for a companion diagnostic AND started up DLBCL. Not a normal thing to do without first seeing WM results. Agrawal knows. Goldman knows. JPM knows. Bakers know. Fidelity knows. Geraghty knows. Milano knows. All of these parties are in at a price 30% above these levels, and they are not in for a 30-cent gain and a whimsical guess.

    From mid September AACR through next year and beyond, there are catalysts one after another. Ph3 WM and DLBCL end of 2017 latest, and 3gA Ph2 same. We're looking at a 10 bagger. All you need is patience and follow the money.

  • frankyassissi by frankyassissi Sep 11, 2015 3:16 PM Flag

    See you over 10 within 4 months

  • frankyassissi by frankyassissi Sep 11, 2015 3:21 PM Flag

    I can't quite remember. Well, I'm sure Milano will let us know next, have some shelled peanuts with that coors light, ya limp noodle

  • frankyassissi by frankyassissi Sep 15, 2015 2:58 PM Flag

    100 over 200 dma. I see 4.50 near term

  • frankyassissi frankyassissi Oct 6, 2015 4:13 PM Flag

    Say no more. The king of tlr's and 3gA. $100 someday....further on up the road, but someday. thx for the post

  • Ask Bio. We're headed to 4+ fast

  • Reply to

    ASH Dec 5-8

    by frankyassissi Oct 31, 2015 12:40 PM
    frankyassissi frankyassissi Oct 31, 2015 12:47 PM Flag

    Furthermore, once results are released, games will continue to claim every single retail share. I am predicting 10-20 by Feb-March when the dust settles. 3gA = billions. Exercise patience and keep reading the scientific PROOF to date.

  • Reply to

    WM Abstract

    by frankyassissi Nov 11, 2015 3:42 PM
    frankyassissi frankyassissi Nov 11, 2015 3:45 PM Flag

    Preliminary evidence of clinical activity for IMO-8400 has been observed in all dose cohorts. In June 2015, an independent Data Review Committee reviewed 4-week safety data from the highest dose cohort and agreed that 2.4 mg/kg was safe for further evaluation. Safety, pharmacokinetics and preliminary activity for all three dose cohorts will be presented.

  • Reply to

    Biggest question mark....

    by ranger43a Nov 5, 2015 4:58 PM
    frankyassissi frankyassissi Nov 5, 2015 5:22 PM Flag

    Hi Ranger. It's Mr Contrarian, lol. ASH has rules regarding data release until presentation. So does AACR.

    The 2125 was presented today, so they could elaborate. That's what draws the crowd. They've got data on patients who have failed all other treatments in WM. Why present garbage at the biggest Cancer Hematology event of the year?

    Quite a few other catalysts as well. GL, my friend.

  • Reply to


    by bonnie_bns Nov 13, 2015 10:18 PM
    frankyassissi frankyassissi Nov 14, 2015 2:18 PM Flag

    Going up without a doubt. WM. 2125 90% rate. Medical miracle

0.4867+0.0478(+10.89%)12:32 PMEST